EDAP TMS SA — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
FocalTherics (formerly EDAP TMS) reported Q2 2026 continuing operations (HIFU segment only) revenue of $13.2M vs. $9.5M YoY (+39%), with gross margin improving to 55.6% from 51.1%. The company sold 13 Focal One systems (vs. 9 prior year) and grew U.S. procedures 47% YoY. Net loss was $14.4M ($0.38/share) vs. $6.4M prior year, driven by $5.5M warrant valuation impact. An underwritten public offering of $40M closed August 14, 2026. ESWL and Distribution segments reclassified as discontinued operations, reflecting strategic shift to focal therapy.
Why this rating
Strong revenue growth and capital raise are meaningful for $61.8M market cap company, but offset by accelerating losses and warrant dilution. Rebranding and strategic refocus provide upside optionality.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.